Cardiorenal effects of an orally active dopamine prodrug (TA-870) in patients with congestive heart failure.
The effects of TA-870, a newly synthesized orally active dopamine prodrug, on the cardiorenal functions were investigated in 12 patients with severe chronic congestive heart failure. A single oral dose of TA-870 (1,200 mg) improved left ventricular fractional shortening and mean circumferential velocity on M-mode echocardiography (p less than 0.01 for both). Renal plasma flow and glomerular filtration rate improved with TA-870 (p less than 0.01 and p less than 0.05, respectively); urine volume and sodium excretion increased (p less than 0.01 for both). Blood pressure and heart rate did not change during the 4-h experimental period. Mean plasma free dopamine levels peaked 1 h after dosing. These data suggest that the cardiorenal effects of oral TA-870 are comparable with those of continuous intravenous injections of dopamine. Thus, TA-870 appears to be a useful alternative drug to intravenous dopamine.
Kubota
J
J
Department of Internal Medicine, Osaka Medical College, Japan.
Kubo
S
S
Nishimura
H
H
Ueyama
M
M
Kino
M
M
Nakayama
A
A
Hara
M
M
Kawamura
K
K
D000328:Adult; D000368:Aged; D004298:Dopamine / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use*; D004452:Echocardiography; D004573:Electrolytes / Q000097:blood; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006334:Heart Function Tests; D006801:Humans; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011355:Prodrugs / Q000097:blood / Q000627:therapeutic use*; D012079:Renal Circulation / Q000187:drug effects; D012964:Sodium / Q000097:blood; D014655:Vascular Resistance / Q000187:drug effects
D004573:Electrolytes; D011355:Prodrugs; D012964:Sodium; C052143:docarpamine; D011188:Potassium; D004298:Dopamine